Literature DB >> 17724443

Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells: analysis of 952 autologous peripheral blood stem cell transplantations.

E Foïs1, M Desmartin, S Benhamida, F Xavier, V Vanneaux, D Rea, J-P Fermand, B Arnulf, N Mounier, M Ertault, J-P Lotz, L Galicier, E Raffoux, M Benbunan, J-P Marolleau, J Larghero.   

Abstract

Cryopreservation and thawing of haematopoietic stem cells are associated with cell loss and infusion-related toxicities. We analysed viability, total nucleated cell (TNC) and CD34+ cell recovery, and infusion-related toxicities of 952 thawed and washed products. Mean TNC and CD34+ viable cells recoveries were 55.9+/-18.6 and 98.0+/-36.5%, respectively. Mean cell viability was 68.25+/-18.9%. TNC recovery was correlated with viability but independent of the initial nucleated cell concentration. No difference in TNC recovery or viability was observed according to underlying diseases, except for myeloma, for which these variables were significantly lower (P<0.05). CD34+ cell recovery was not correlated with viability or CD34+ initial count and was similar for all diseases. Cryostorage duration was not associated with cell loss. Immediate adverse events occurred in 169 patients (19%) and were moderate (grade I or II) for the majority of patients. Clinical toxicity was associated with a higher infused cell number and the presence of clumps in infused bags. The washing procedure of cell products lead to a low rate of adverse events, but patients transplanted with high cell numbers or bags in which clumps were identified are predisposed to such complications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724443     DOI: 10.1038/sj.bmt.1705830

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Infused neutrophil dose and haematopoietic recovery in patients undergoing autologous transplantation.

Authors:  L Bai; W Xia; K Wong; C Reid; C Ward; M Greenwood
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

2.  Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftment.

Authors:  Nandita Khera; Jack Jinneman; Barry E Storer; Shelly Heimfeld; Megan M O'Meara; Thomas R Chauncey; Stephanie J Lee; Michael Linenberger
Journal:  Biol Blood Marrow Transplant       Date:  2011-06-15       Impact factor: 5.742

3.  How old is too old? In vivo engraftment of human peripheral blood stem cells cryopreserved for up to 18 years - implications for clinical transplantation and stability programs.

Authors:  John Underwood; Mahvish Rahim; Carijo West; Rebecca Britton; Elaine Skipworth; Vicki Graves; Steven Sexton; Hillary Harris; Dave Schwering; Anthony Sinn; Karen E Pollok; Kent A Robertson; W Scott Goebel; Kerry M Hege
Journal:  World J Stem Cells       Date:  2020-05-26       Impact factor: 5.326

Review 4.  Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion.

Authors:  Z Shu; S Heimfeld; D Gao
Journal:  Bone Marrow Transplant       Date:  2013-09-30       Impact factor: 5.483

5.  Adverse reactions of dimethyl sulfoxide in humans: a systematic review.

Authors:  Bennedikte Kollerup Madsen; Maria Hilscher; Dennis Zetner; Jacob Rosenberg
Journal:  F1000Res       Date:  2018-11-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.